文献速递重症综合管理与镇静镇痛

乙酰胆碱酯酶抑制剂预防谵妄:系统评价与Meta分析

Acetylcholinesterase Inhibitors for Delirium Prevention: A Systematic Review and Meta-Analysis.
PubMed 文献 · Crit Care Med · 2025-08-05
一句话结论择期手术患者预防性使用乙酰胆碱酯酶抑制剂可降低谵妄发生率(RR=0.68),但未显著缩短谵妄持续时间、严重程度或住院时长。

该系统评价与Meta分析检索PubMed、Embase和Web of Science,纳入10项比较乙酰胆碱酯酶抑制剂(AChEIs)与安慰剂的研究,共731例患者(AChEIs组365例,安慰剂组366例),其中8项为术后谵妄预防、2项为已发生谵妄的治疗。AChEIs显著降低谵妄发生率(RR=0.68,95%CI 0.47-0.98,P=0.039),但对谵妄持续时间(MD=-0.16天,95%CI -0.9至0.62天,P=0.23)、严重程度(SMD=-0.08,95%CI -0.58至0.41,P=0.74)和住院时长(MD=-0.82天,95%CI -2.03至0.40天,P=0.19)无显著影响。亚组分析显示预防性使用时谵妄持续时间显著缩短(SMD=-0.32,95%CI -0.56至-0.07,P<0.01),不良事件无显著差异。作者结论认为AChEIs在择期手术患者中预防性使用可有效减少谵妄发生,需进一步研究不同人群和场景中的获益或危害。

要点

  • 择期手术患者预防性使用AChEIs可降低谵妄发生率:AChEIs组 vs 安慰剂组 RR=0.68(95%CI 0.47-0.98,P=0.039)。
  • AChEIs对谵妄持续时间无显著影响:MD=-0.16天(95%CI -0.9至0.62天,P=0.23)。
  • AChEIs对谵妄严重程度无显著影响:SMD=-0.08(95%CI -0.58至0.41,P=0.74)。
  • AChEIs对住院时长无显著影响:MD=-0.82天(95%CI -2.03至0.40天,P=0.19)。
  • 预防性使用亚组中谵妄持续时间显著缩短:SMD=-0.32(95%CI -0.56至-0.07,P<0.01);不良事件无显著差异。

适用人群与场景

  • 住院患者,共731例(AChEIs组365例,安慰剂组366例),纳入8项术后谵妄预防研究和2项已发生谵妄的治疗研究。

研究设计与关键结果

  • 系统评价与Meta分析,检索PubMed、Embase和Web of Science,筛选1306条记录后纳入10项研究(8项术后预防、2项已发生谵妄治疗),共731例患者(AChEIs组365例 vs 安慰剂组366例)。
  • AChEIs显著降低谵妄发生率:RR=0.68(95%CI 0.47-0.98,P=0.039)。
  • 谵妄持续时间无显著差异:MD=-0.16天(95%CI -0.9至0.62天,P=0.23)。
  • 谵妄严重程度无显著差异:SMD=-0.08(95%CI -0.58至0.41,P=0.74)。
  • 住院时长无显著差异:MD=-0.82天(95%CI -2.03至0.40天,P=0.19)。
  • 预防性使用亚组中谵妄持续时间显著缩短:SMD=-0.32(95%CI -0.56至-0.07,P<0.01)。
  • 不良事件无显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,采用随机效应模型,异质性以I²评估,偏倚风险采用Risk of Bias 2评估,研究注册于PROSPERO(CRD42024563798)。
  • 局限:作者指出需进一步研究以探索AChEIs在不同患者人群和场景中的潜在获益或危害。

对床旁实践的改变

  • 作者结论认为,AChEIs在择期手术患者中预防性使用可有效减少谵妄发生;AChEIs对谵妄持续时间、严重程度或住院时长无显著影响。
  • 作者指出需进一步研究以探索AChEIs在不同患者人群和场景中的潜在获益或危害。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Delirium is a frequent complication in hospitalized patients, particularly in older adults, and is associated with significant morbidity and mortality. Acetylcholinesterase inhibitors (AChEIs) have been proposed as potential agents to reduce occurrence and severity of delirium. This study aimed to evaluate the efficacy of AChEIs for both prophylaxis and treatment of delirium in hospitalized patients.

DATA SOURCES: We searched PubMed, Embase, and Web of Science. The study was registered on PROSPERO (CRD42024563798).

STUDY SELECTION: Studies comparing AChEIs and placebo for delirium in hospitalized patients.

DATA EXTRACTION: The main outcome of interest was delirium occurrence, while secondary outcomes included duration, severity, and hospital length of stay (LOS).

DATA SYNTHESIS: Subgroup analyses were performed based on prophylaxis or treatment of delirium. Statistical analysis was performed in RStudio 4.4.0 with a random effects model, and heterogeneity was assessed with I2 . Risk of Bias 2 was used for bias assessment. We screened 1306 records and included ten studies: eight studies focusing on prophylaxis after surgery and two on treatment of established delirium. A total of 731 patients were analyzed: 365 in the AChEIs group and 366 in the placebo group. AChEIs significantly reduced delirium occurrence (risk ratio = 0.68 [0.47-0.98]; p = 0.039). No significant effects were observed for delirium duration (mean difference [MD] = -0.16 d [-0.9 to 0.62 d]; p = 0.23), delirium severity (standardized mean difference [SMD] = -0.08 [-0.58 to 0.41]; p = 0.74), or LOS (MD = -0.82 d [-2.03 to 0.40 d]; p = 0.19). Subgroup analysis showed a tendency for better outcomes when AChEIs were used as prophylaxis, with a significant reduction in delirium duration in this subgroup (SMD= -0.32 [-0.56 to -0.07]; p < 0.01). No significant differences in adverse events were identified.

CONCLUSIONS: AChEIs are effective in reducing occurrence of delirium when used prophylactically in patients undergoing elective surgery. AChEIs did not significantly impact on delirium duration, severity, or hospital LOS. Further studies are needed to explore the potential benefits or harms of AChEIs in different patient populations and settings.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Pipek LZ, Pascual GS, Nascimento RFV, et al. Acetylcholinesterase Inhibitors for Delirium Prevention: A Systematic Review and Meta-Analysis. Crit Care Med. 2025. PMID: 40758382. doi:10.1097/CCM.0000000000006786

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。